Skip to main content

Table 3 Subjects with PD, DLB and ILBD exhibit specific tau and Aβ deposits in pancreatic β cells

From: Mixed pathologies in pancreatic β cells from subjects with neurodegenerative diseases and their interaction with prion protein

Groups pSer202-Thr205 pThr212-Ser214 pThr231 pThr181 pSer262 Tau pSer 422 Tau Oligomeric Tau Asp421-cleaved Tau Tau Tau Aβ (4G8)
Tau Tau Tau Tau Alz50 MC1
Incidental Lewy body disease 7/8 (88%) 6/8 (75%) 1/8 (13%) 8/8 (100%) 8/8 (100%) 5/8 (63%) 10/10 (100%) 6/8 (75%) 6/8 (75%) 2/8 (25%) 2/8 (25%)
Parkinson's disease 10/10 (100%) 9/10 (90%) 4/10 (40%) 10/10 (100%) 10/10 (100%) 8/10 (80%) 8/10 (80%) 8/10 (80%) 10/10 (100%) 4/10 (40%) 3/10 (30%)
Dementia with Lewy bodies 12/12 (100%) 12/12 (100%) 7/12 (58%) 12/12 (100%) 12/12 (100%) 10/12 (83%) 9/12 (83%) 10/12 (83%) 12/12 (100%) 5/12 (42%) 4/12 (33%)
Normal neuropathological examination* 15/29 (52%) 14/29 (48%) 7/29 (24%) 24/29 (83%) 26/29 (90%) 12/29 (41%) 7/29 (24%) 6/29 (21%) 23/29 (79%) 4/29 (14%) 3/29 (10%)
Normal neuropathological examination with T2DM* 13/19 (68%) 19/19 (53%) 7/19 (37%) 17/19 (89%) 19/19 (100%) 8/19 (42%) 10/19 (53%) 6/19 (32%) 15/19 (79%) 6/19 (32%) 3/19 (16%)
Alzheimer disease with a low neuropathologic change* 22/28 (79%) 24/28 (86%) 14/28 (50%) 21/28 (75%) 28/28 (100%) 17/28 (61%) 21/28 (75%) 11/28 (39%) 24/28 (86%) 9/28 (32%) 10/28 (36%)
Alzheimer disease with an intermediate neuropathologic change* 22/26 (85) 24/26 (92%) 14/26 (54%) 23/26 (88%) 26/26 (100%) 18/26 (69%) 22/26 (85%) 12/26 (46%) 25/26 (96%) 12/26 (46%) 10/26 (38%)
Alzheimer disease with a high neuropathologic change* 8/8 (100%) 8/8 (100%) 5/8 (63%) 8/8 (100%) 8/8 (100%) 4/8 (50%) 7/8 (88%) 7/8 (88%) 8/8 (100%) 7/8 (88%) 4/8 (50%)
  1. The data are represented as n (%). PD, Parkinson’s disease; DLB, dementia with Lewy bodies; ILBD, incidental Lewy body disease. Tau AT-8, Ser202-Thr205-phosphorylated tau; Tau AT-100, Thr212-Ser214-phosphorylated tau; Tau AT-180, Thr231-phosphorylated tau; Tau AT-270, Thr181-phosphorylated tau; and pTau, phosphorylated tau. *These results had been previously published in Martinez-Valbuena et al. 2019 and have been added in this table to facilitate comparisons between groups